酪氨酸激酶抑制剂的眼部毒性
Ocular Toxicity of Tyrosine Kinase Inhibitors.
作者信息
Davis Mary Elizabeth
机构信息
Department of Ambulatory Nursing, Memorial Sloan-Kettering Cancer Center, New York, NY.
出版信息
Oncol Nurs Forum. 2016 Mar;43(2):235-43. doi: 10.1188/16.ONF.235-243.
Abstract
PURPOSE/OBJECTIVES: To review common tyrosine kinase inhibitors, as well as their ocular side effects and management. .
DATA SOURCES
A comprehensive literature search was conducted using CINAHL®, PubMed, and Cochrane databases for articles published since 2004 with the following search terms.
DATA SYNTHESIS: Tyrosine kinase inhibitors can cause significant eye toxicity. .
CONCLUSIONS: Given the prevalence of new tyrosine kinase inhibitor therapies and the complexity of possible pathogenesis of ocular pathology, oncology nurses can appreciate the occurrence of ocular toxicities and the role of nursing in the management of these problems. .
IMPLICATIONS FOR NURSING
Knowledge of the risk factors and etiology of ocular toxicity of targeted cancer therapies can guide nursing assessment, enhance patient education, and improve care management. Including a review of eye symptoms and vision issues in nursing assessment can enhance early detection and treatment of ocular toxicity.
摘要
目的/目标：回顾常见的酪氨酸激酶抑制剂及其眼部副作用和处理方法。
数据来源
使用CINAHL®、PubMed和Cochrane数据库进行了全面的文献检索，以查找自2004年以来发表的文章，检索词如下。
数据综合
酪氨酸激酶抑制剂可导致严重的眼部毒性。
结论
鉴于新型酪氨酸激酶抑制剂疗法的广泛应用以及眼部病变可能发病机制的复杂性，肿瘤学护士应了解眼部毒性的发生情况以及护理在这些问题管理中的作用。
对护理的启示
了解靶向癌症治疗眼部毒性的危险因素和病因可指导护理评估、加强患者教育并改善护理管理。在护理评估中纳入对眼部症状和视力问题的检查可提高眼部毒性的早期发现和治疗。
相似文献
1
Ocular Toxicity of Tyrosine Kinase Inhibitors.酪氨酸激酶抑制剂的眼部毒性
Oncol Nurs Forum. 2016 Mar;43(2):235-43. doi: 10.1188/16.ONF.235-243.
2
Managing Chemotherapy Side Effects: Achieving Reliable and Equitable Outcomes.管理化疗副作用：实现可靠且公平的结果。
Clin J Oncol Nurs. 2016 Dec 1;20(6):589-591. doi: 10.1188/16.CJON.589-591.
3
Optic and otic side effects of molecular targeted therapies.分子靶向治疗的眼部和耳部副作用。
Semin Oncol Nurs. 2014 Aug;30(3):169-74. doi: 10.1016/j.soncn.2014.05.004.
4
Early Recognition and Management of Posterior Reversible Encephalopathy Syndrome: A Newly Recognized Complication in Patients Receiving Tyrosine Kinase Inhibitors.
Clin J Oncol Nurs. 2016 Jun 1;20(3):305-8. doi: 10.1188/16.CJON.305-308.
5
Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer.转移性结直肠癌抗 EGFR 相关毒性管理的最佳实践。
Eur J Oncol Nurs. 2010 Sep;14(4):337-49. doi: 10.1016/j.ejon.2010.03.004. Epub 2010 May 23.
6
Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma.转移性肾细胞癌中索拉非尼、舒尼替尼和替西罗莫司毒性的管理。
Curr Opin Support Palliat Care. 2009 Sep;3(3):170-9. doi: 10.1097/SPC.0b013e32832e4681.
7
Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders.非小细胞肺癌治疗中的新出现的毒性作用：眼部疾病。
Cancer Treat Rev. 2014 Feb;40(1):197-203. doi: 10.1016/j.ctrv.2013.05.005. Epub 2013 Jul 10.
8
Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors.拉帕替尼：一种对实体瘤有活性的新型双靶点酪氨酸激酶抑制剂。
Ann Pharmacother. 2006 Feb;40(2):261-9. doi: 10.1345/aph.1G387. Epub 2006 Jan 17.
9
Assessment and management of gastrointestinal toxicities and lab abnormalities related to targeted therapy.与靶向治疗相关的胃肠道毒性和实验室异常的评估与管理。
Semin Oncol Nurs. 2014 Aug;30(3):183-9. doi: 10.1016/j.soncn.2014.05.006.
10
Oncology Nursing Considerations in a Clinical Trials Environment.肿瘤护理学在临床试验环境中的考虑因素。
Semin Oncol Nurs. 2020 Jun;36(3):151020. doi: 10.1016/j.soncn.2020.151020. Epub 2020 May 27.
引用本文的文献
1
Bilateral optic neuropathy associated with lorlatinib monotherapy for ALK-positive metastatic lung adenocarcinoma.与劳拉替尼单药治疗ALK阳性转移性肺腺癌相关的双侧视神经病变
Am J Ophthalmol Case Rep. 2024 Apr 25;34:102063. doi: 10.1016/j.ajoc.2024.102063. eCollection 2024 Jun.
2
Bilateral keratitis associated with afatinib therapy.与阿法替尼治疗相关的双侧角膜炎。
Taiwan J Ophthalmol. 2024 Feb 23;14(1):121-124. doi: 10.4103/tjo.TJO-D-24-00003. eCollection 2024 Jan-Mar.
3
Radiation Therapy in the Management of Leptomeningeal Disease From Solid Tumors.实体瘤软脑膜疾病治疗中的放射治疗
Adv Radiat Oncol. 2023 Sep 15;9(2):101377. doi: 10.1016/j.adro.2023.101377. eCollection 2024 Feb.
4
Spontaneous Hyphema during Ibrutinib Treatment in a CLL Patient.一名慢性淋巴细胞白血病患者在接受依鲁替尼治疗期间出现自发性前房积血。
Case Rep Hematol. 2023 Dec 14;2023:1691996. doi: 10.1155/2023/1691996. eCollection 2023.
5
Ocular complications of antineoplastic therapies.抗肿瘤治疗的眼部并发症。
Future Sci OA. 2023 Jun 1;9(7):FSO871. doi: 10.2144/fsoa-2022-0081. eCollection 2023 Aug.
6
Ocular side effects of Trametinib and Dabrafenib: a case report.曲美替尼和达拉非尼的眼部副作用：一例报告
J Ophthalmic Inflamm Infect. 2023 Apr 12;13(1):17. doi: 10.1186/s12348-023-00339-0.
7
Suspected Neratinib Macular Toxicity Presenting As Macular Telangiectasia Type II.表现为II型黄斑毛细血管扩张症的奈拉替尼黄斑毒性疑似病例。
Cureus. 2023 Jan 19;15(1):e33964. doi: 10.7759/cureus.33964. eCollection 2023 Jan.
8
Targeted Cancer Therapy and Its Ophthalmic Side Effects: A Review.靶向癌症治疗及其眼部副作用：综述
J Immunother Precis Oncol. 2021 Feb 25;4(1):6-15. doi: 10.36401/JIPO-20-21. eCollection 2021 Feb.
9
Ibrutinib-related uveitis: A case series.依鲁替尼相关性葡萄膜炎：病例系列
Am J Ophthalmol Case Rep. 2022 Jan 22;25:101300. doi: 10.1016/j.ajoc.2022.101300. eCollection 2022 Mar.
10
In Vivo Efficacy of Imatinib Mesylate, a Tyrosine Kinase Inhibitor, in the Treatment of Chemically Induced Dry Eye in Animal Models.甲磺酸伊马替尼（一种酪氨酸激酶抑制剂）在治疗化学诱导的动物模型干燥眼中的体内疗效。
Transl Vis Sci Technol. 2021 Sep 1;10(11):14. doi: 10.1167/tvst.10.11.14.
本文引用的文献
1
Ocular Toxicity in Metastatic Melanoma Patients Treated With Mitogen-Activated Protein Kinase Kinase Inhibitors: A Case Series.丝裂原活化蛋白激酶激酶抑制剂治疗转移性黑色素瘤患者的眼部毒性：病例系列
Am J Ophthalmol. 2015 Nov;160(5):959-967.e1. doi: 10.1016/j.ajo.2015.07.035. Epub 2015 Jul 29.
2
MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity.MEK抑制剂：一类具有眼部毒性的新型化疗药物。
Eye (Lond). 2015 Aug;29(8):1003-12. doi: 10.1038/eye.2015.82. Epub 2015 Jun 5.
3
Essential fatty acids in the treatment of dry eye syndrome: A myth or reality?必需脂肪酸治疗干眼症：神话还是现实？
Saudi J Ophthalmol. 2014 Jul;28(3):195-7. doi: 10.1016/j.sjopt.2014.06.004. Epub 2014 Jun 24.
4
Aging: a predisposition to dry eyes.衰老：干眼症的一个易感因素。
J Ophthalmol. 2014;2014:781683. doi: 10.1155/2014/781683. Epub 2014 Aug 14.
5
Ophthalmic complications of targeted cancer therapy and recently recognized ophthalmic complications of traditional chemotherapy.靶向癌症治疗的眼科并发症以及近期发现的传统化疗的眼科并发症。
Surv Ophthalmol. 2014 Sep-Oct;59(5):493-502. doi: 10.1016/j.survophthal.2014.02.004. Epub 2014 Feb 18.
6
Managing Sjögren's Syndrome and non-Sjögren Syndrome dry eye with anti-inflammatory therapy.采用抗炎疗法治疗干燥综合征和非干燥综合征性干眼
Clin Ophthalmol. 2014 Aug 4;8:1447-58. doi: 10.2147/OPTH.S35685. eCollection 2014.
7
Retinal toxicities of cancer therapy drugs: biologics, small molecule inhibitors, and chemotherapies.癌症治疗药物的视网膜毒性：生物制剂、小分子抑制剂和化疗药物。
Retina. 2014 Jul;34(7):1261-80. doi: 10.1097/IAE.0000000000000242.
8
A randomized controlled trial of omega-3 fatty acids in dry eye syndrome.一项关于ω-3脂肪酸治疗干眼症综合征的随机对照试验。
Int J Ophthalmol. 2013 Dec 18;6(6):811-6. doi: 10.3980/j.issn.2222-3959.2013.06.13. eCollection 2013.
9
Ocular side effects of biological agents in oncology: what should the clinician be aware of?肿瘤学中生物制剂的眼部副作用：临床医生应注意什么？
Onco Targets Ther. 2013 Dec 24;7:69-77. doi: 10.2147/OTT.S54606.
10
Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review.已批准用于实体瘤的分子靶向药物的眼部不良事件：系统评价。
Eur J Cancer. 2014 Feb;50(3):638-48. doi: 10.1016/j.ejca.2013.10.016. Epub 2013 Nov 17.
Zotero 插件